News >

Precision Medicine Impact Grows in GI Cancer Paradigm

Danielle Bucco
Published: Friday, Mar 30, 2018

Bert O’Neil, MD

Bert O’Neil, MD
The development of molecular testing and next-generation sequencing throughout the oncology space has also been applied to gastrointestinal (GI) cancers management, in an effort to better identify molecular alterations and optimize treatment decisions.

State of the Science Summit™ on Gastrointestinal Cancers, O’Neil, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discussed the role of molecular testing throughout GI cancers and highlighted the current and developing treatment landscape for patients with colorectal cancer (CRC).

OncLive: You spoke on precision medicine in GI cancers as well as a specific focus on mCRC. How have you seen the GI cancers paradigm evolve?

O’Neil: We are now well into this area of precision medicine, which involves genetic sequencing of tumors to look for treatment options that we might not have considered for patients with a particular tumor type in the past. It is an exciting time.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Navigating Treatment Decisions in mCRC: Sequencing Through Multiple Lines of CareMar 26, 20201.5
Community Practice Connections™: Optimizing Care in the Era of an Expanding Armamentarium for Hepatocellular CarcinomaMar 29, 20202.0
Publication Bottom Border
Border Publication
x